Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Population‐based cellular kinetic characterization of ciltacabtagene autoleucel in subjects with relapsed or refractory multiple myeloma

6 Oct 2022

Abstract excerpt

Abstract The aims of this work were to develop a population pharmacokinetic (PK) model for chimeric antigen receptor (CAR) transgene after single intravenous infusion administration of ciltacabtagene autoleucel in adult patients with relapsed or refractory multiple myeloma. CAR transgene level in blood were measured by quantitative polymerase chain reaction (qPCR) from 97 subjects in a phase Ib/II CARTITUDE‐1...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to CAR-T cell therapy research
Share to Monoclonal and Polyclonal Antibodies Research
Share to Viral Infectious Diseases and Gene Expression in Insects

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 36204820
DOI: 10.1111/cts.13421

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Population‐based cellular kinetic characterization of ciltacabtagene autoleucel in subjects with relapsed or refractory multiple myelomaPMID 36204820Read ↗

Computational modelling of CAR T-cell therapy: from cellular kinetics to patient-level predictionsSemantic proximity Read ↗

A longitudinal single-cell atlas to predict outcome and toxicity after BCMA-directed CAR T cell therapy in multiple myelomaSemantic proximity Read ↗

Outcomes of CAR T-Cell Therapy in Relapsed/Refractory Multiple Myeloma by Race: A Multicenter Real-World StudySemantic proximity Read ↗

Three-Compartment Model of CAR T-cell ImmunotherapySemantic proximity Read ↗

Deconvolution of clinical variance in CAR-T cell pharmacology and responseSemantic proximity Read ↗

Modeling Patient-Specific CAR-T Cell Dynamics: Multiphasic Kinetics Via Phenotypic DifferentiationSemantic proximity Read ↗

Modeling Patient-Specific CAR-T Cell Dynamics: Multiphasic Kinetics via Phenotypic DifferentiationSemantic proximity Read ↗

Mechanisms of Resistance to CAR-T cell Immunotherapy: Insights from a Mathematical ModelSemantic proximity Read ↗

Quantitative Prediction of Human Pharmacokinetics for Fc-Engineered Therapeutic Monoclonal Antibodies With Increased FcRn Binding Mutations After Subcutaneous Injection.Semantic proximity Read ↗

Population Pharmacokinetic Modeling of Encorafenib in Healthy Participants and Patients with BRAF V600-Mutant Solid Tumors: A Semi-mechanistic Autoinduction Model.Semantic proximity Read ↗

Serum albumin: a pharmacokinetic marker for optimizing treatment outcome of immune checkpoint blockade.Semantic proximity Read ↗

The roles of T cell competition and stochastic extinction events in chimeric antigen receptor T cell therapySemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.